Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced tumor disease.

In contrast, the study revealed a highly significant difference when comparing the influence of SPC on EOL SACT solely within the patient cohort that received SACT ( P = 0.009).

also in 132,142 other papers

1 In our study, we also observed a clear trend where patients ≤65 years of age were more likely to receive EOL SACT.

also in 19,460 other papers

revealed that 14% of their patients even received anticancer treatments in the last 2 weeks of life, with an increasing trend in the use of novel therapies such as targeted therapy and immunotherapy. 1 Understanding the factors influencing EOL SACT is pivotal for optimizing treatment decisions in advanced cancer care.

also in 63,971 other papers